Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient engagement platform with automated SMS reminders, self-scheduling, and EHR integration for health systems; $130M+ a16z-backed competing with Phreesia for healthcare communication automation.
Luma Health is a San Francisco-based patient engagement and care orchestration platform that automates patient communication and administrative workflows for healthcare providers — providing appointment reminders, two-way SMS messaging, self-scheduling, waitlist management, referral coordination, and broadcast messaging that integrate directly with major electronic health record (EHR) systems including Epic, Cerner, Athenahealth, and eClinicalWorks. Backed by Andreessen Horowitz and other investors with $130+ million raised, Luma Health serves health systems, hospital groups, and ambulatory practices seeking to reduce no-shows and improve patient access.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.